Somewhat Positive Media Coverage Somewhat Unlikely to Affect La Jolla Pharmaceutical (LJPC) Stock Price

Media headlines about La Jolla Pharmaceutical (NASDAQ:LJPC) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. La Jolla Pharmaceutical earned a news impact score of 0.07 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.1590857223291 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of brokerages have commented on LJPC. Zacks Investment Research lowered La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. Cowen restated a “buy” rating and set a $55.00 price objective on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. BidaskClub upgraded La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Jefferies Group lowered La Jolla Pharmaceutical from a “buy” rating to an “underperform” rating and decreased their price objective for the stock from $40.00 to $29.00 in a research report on Monday, February 12th. Finally, ValuEngine upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Four analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. La Jolla Pharmaceutical presently has a consensus rating of “Hold” and an average target price of $55.86.

How to Become a New Pot Stock Millionaire

LJPC opened at $30.48 on Friday. La Jolla Pharmaceutical has a fifty-two week low of $22.68 and a fifty-two week high of $41.36. The stock has a market cap of $793.54, a PE ratio of -5.63 and a beta of 1.36.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.25) by ($0.49). equities research analysts anticipate that La Jolla Pharmaceutical will post -4.94 earnings per share for the current fiscal year.

In other news, major shareholder Perceptive Advisors Llc purchased 700,000 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was bought at an average cost of $29.50 per share, with a total value of $20,650,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Kevin C. Tang purchased 508,474 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were purchased at an average cost of $29.50 per share, with a total value of $14,999,983.00. The disclosure for this purchase can be found here. Insiders have bought a total of 1,544,474 shares of company stock valued at $46,485,863 over the last ninety days. Company insiders own 25.47% of the company’s stock.

WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect La Jolla Pharmaceutical (LJPC) Stock Price” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-la-jolla-pharmaceutical-ljpc-stock-price.html.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Insider Buying and Selling by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply